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Abstract
The National Influenza Program aims to reduce 
serious morbidity and mortality from influenza 
by providing public funding for vaccination to 
at-risk groups. The Influenza Complications Alert 
Network (FluCAN) is a sentinel hospital-based 
surveillance program that operates at 14 sites in 
all states and territories in Australia. This report 
summarises the epidemiology of hospitalisations 
with confirmed influenza, estimates vaccine cov-
erage and influenza vaccine protection against 
hospitalisation with influenza during the 2013 
influenza season. In this observational study, cases 
were defined as patients admitted to one of the 
sentinel hospitals, with influenza confirmed by 
nucleic acid testing. Controls were patients who 
had acute respiratory illnesses who were test-
negative for influenza. Vaccine effectiveness was 
estimated as 1 minus the odds ratio of vaccination 
in case patients compared with control patients, 
after adjusting for known confounders. During the 
period 5 April to 31 October 2013, 631 patients 
were admitted with confirmed influenza at the 
14 FluCAN sentinel hospitals. Of these, 31% were 
more than 65 years of age, 9.5% were Indigenous 
Australians, 4.3% were pregnant and 77% had 
chronic co-morbidities. Influenza B was detected 
in 30% of patients. Vaccination coverage was esti-
mated at 81% in patients more than 65 years of age 
but only 49% in patients aged less than 65 years 
with chronic comorbidities. Vaccination effective-
ness against hospitalisation with influenza was 
estimated at 50% (95% confidence interval: 33%, 
63%, P<0.001). We detected a significant number 
of hospital admissions with confirmed influenza in 
a national observational study. Vaccine coverage 
was incomplete in at-risk groups, particularly non-
elderly patients with medical comorbidities. Our 
results suggest that the seasonal influenza vaccine 
was moderately protective against hospitalisation 
with influenza in the 2013 season. Commun Dis 
Intell 2014;38(2):E143–E149.
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Introduction
Influenza vaccination is recommended in Australia 
for high risk groups, including the elderly, patients 
with chronic comorbidities, pregnant women 
and Indigenous Australians.1 The National 
Immunisation Program, which provides public 
funding for influenza and other vaccinations, 
aims to reduce serious morbidity and mortality 
from influenza. Clinical trials have shown that the 
influenza vaccine is moderately protective against 
influenza2 but fewer studies have examined its 
effectiveness in reducing serious complications, as 
the proportion of cases requiring hospitalisation 
is low. However, because infection with influenza 
virus is relatively widespread and estimated to 
affect 5%–10% of the population, the incidence of 
hospitalisation from influenza is of public health 
significance.
The Influenza Complications Alert Network 
(FluCAN) was established in 2009 primarily 
to provide timely surveillance to public health 
authorities nationally on hospitalisations with con-
firmed influenza.3 In this report, we describe the 
epidemiology of hospitalisation with confirmed 
influenza, estimate vaccine coverage in hospital-
ised patients with acute respiratory illnesses but 
without influenza, and estimate influenza vaccine 
protection against hospitalisation with influenza 
during the 2013 influenza season.
Methods
FluCAN is a national hospital-based sentinel sur-
veillance system.3 For the 2 most recent influenza 
seasons including 2013, the participating sites have 
been The Alfred Hospital (Vic.), Royal Melbourne 
Hospital (Vic.), Canberra Hospital (ACT), 
Monash Medical Centre (Vic.), Geelong Hospital 
(Vic.), Royal Perth Hospital (WA), Royal Adelaide 
Hospital (SA), Royal Hobart Hospital (Tas.), 
Mater Hospital (Qld), Princess Alexandra Hospital 
(Qld), Cairns Base Hospital (Qld), Alice Springs 
Hospital (NT), Westmead Hospital (NSW), and 
John Hunter Hospital (NSW). Ethical approval 
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has been obtained at all participating sites, at 
Monash University and the Australian National 
University.
Definitions
An influenza case was defined as a patient admit-
ted to hospital with influenza confirmed by nucleic 
acid testing (NAT). Surveillance was conducted 
from 5 April to 31 October 2013. Test negative 
controls (one for each case where available) were 
the next tested patient with acute respiratory symp-
toms who was negative for influenza by NAT. 
Admission or transfer to intensive care unit (ICU) 
included patients managed in a high dependency 
unit. The onset date was defined as the date of 
admission except for patients where the date of the 
test was more than 7 days after admission, where 
the onset date was the date of the test. Admissions 
that are listed as influenza A include both untyped 
and seasonal strains, and may include infections 
involving the pandemic H1N1/09 strain if not 
specifically typed.
Estimation of vaccination coverage and 
effectiveness
Vaccination coverage was estimated from patients 
admitted with influenza-like illness but who were 
negative for influenza by NAT. Patients were 
defined as being vaccinated if they reported  receiv-
ing the 2013 trivalent seasonal vaccine more than 
2 weeks prior to presentation (as documented in the 
medical record or from self-report). In Australia, 
only unadjuvanted vaccines are available under 
the National Immunisation Program although 
1 adjuvanted vaccine is approved for use. Nasally 
administered live attenuated and quadrivalent 
influenza vaccines are not available in Australia.
We used an incidence density test negative design 
to estimate vaccine effectiveness, where controls are 
selected from patients without influenza contem-
poraneous to a case.4–6 Vaccine effectiveness was 
estimated as 1 minus the odds ratio of vaccination 
in case patients compared with test negative con-
trol patients using methods previously described.7,8 
A multi-variable model was constructed from fac-
tors known to be associated with both vaccination 
and risk of illness, and therefore were regarded as 
potential confounders.
Results
During the period 5 April to 31 October 2013, 
631 patients were admitted with confirmed 
influenza infection at the 14 FluCAN sentinel 
hospitals. In most jurisdictions, the peak number 
of hospitalised cases varied between late August 
and late October 2013 (Figure 1). The majority 
of cases were due to influenza A, but 30% were 
due to influenza B; however, the proportion due 
to influenza B varied from 2 of 50 cases (4%) at 
Alice Springs Hospital to 27 of 47 cases (57%) at 
Geelong Hospital.
Figure 1: Date of admission for patients hospitalised with confirmed influenza
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Of these 631 patients, 200 (32%) were more 
than 65 years of age, 60 (9.5%) were Indigenous 
Australians, 27 (4.3%) were pregnant and 
488 (77%) had chronic co-morbidities (Table 1). Of 
the 514 patients (81%) of patients where influenza 
vaccination status was ascertained, 199 (31%) had 
been vaccinated. Factors associated with admission 
with confirmed influenza, compared with admis-
sion with non-influenza controls are detailed in 
Table 2. As there was no community-based control 
group, factors associated with hospital admission 
could not be quantified, but it was noted that 77% 
Table 1: Demographics, risk factors and outcomes in hospitalised patients with confirmed 
influenza
2012 2013
Number Proportion Number Proportion
Demographics
Number of patients 1,231 631
Age group
<18 years 148 12.0 32 5.1
18–<40 years 229 18.6 139 22.0
40–<65 years 281 22.8 260 41.2
65–<80 years 307 24.9 131 20.8
≥80 years 266 21.6 69 10.9
Male 614 49.9 314 49.8
Indigenous 99 8.0 60 9.5
State or territory
ACT 105 8.5 35 5.5
NSW 84 6.8 125 19.8
NT 83 6.7 50 7.9
Qld 167 13.6 29 4.6
SA 200 16.3 109 17.3
Tas. 99 8.0 30 4.8
Vic. 390 31.7 202 32.0
WA 103 8.4 51 8.1
Influenza strain
H1N1/09 12 1.0 167 26.5
Flu A (unknown/seasonal) 1,006 81.7 277 43.9
Flu B 213 17.3 187 29.6
Risk factors
Pregnant 39 3.2 27 4.3
Nursing home resident 68 5.5 18 2.8
Medical co-morbidities 944 76.7 488 77.3
Chronic respiratory disease 446 36.2 226 35.7
Diabetes 260 21.1 136 21.6
Chronic liver disease 38 3.1 38 6.0
Immunosuppressed 217 17.6 155 24.6
Chronic cardiac disease 353 28.7 183 29.0
Chronic neurological disease 175 14.2 94 14.8
Chronic renal disease 116 9.4 76 12.0
Severity and outcome
Initial admitting ward
General ward 1,123 91.2 561 88.6
High dependency or intensive care unit 108 8.8 69 10.9
In-hospital mortality 40/1,157 3.5 20/621 3.2
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of patients had medical comorbidities. The most 
commonly reported co-morbidities were respira-
tory disease, cardiac disease, immunosuppression 
and diabetes.
Clinical course, severity and outcome
In 609 patients with confirmed influenza where 
the duration of symptoms was known, the median 
duration of symptoms prior to admission was 
3 days (interquartile range (IQR) 2, 5 days). In 
patients with confirmed influenza, 347 (54%) 
received oseltamivir. Of these, 142 patients received 
oseltamivir within 48 hours of symptom onset. The 
duration of hospital stay was similar for patients 
that did not receive antivirals (median 4 days, 
IQR 2, 8 days), received antivirals within 48 hours 
of symptom onset (4 days, IQR 2, 8 days) and who 
received antivirals more than 48 hours after symp-
tom onset (5 days, IQR 3, 10 days).
Of all cases, 69 (11%) were initially admitted to ICU 
and a further 33 patients were subsequently trans-
ferred to ICU after initial admission to a general 
ward. In a multivariate model stratified by hospital 
site, more than 65 years of age and pregnancy 
were negatively associated with ICU admission in 
hospitalised patients with confirmed influenza, 
while the presence of medical comorbidities was 
positively associated with ICU admission (Table 3). 
Indigenous patients were more likely to be admit-
ted to ICU, but this difference was not statistically 
significant. In patients where influenza vaccina-
tion status was ascertained, influenza vaccination 
was negatively associated with ICU admission 
(odds ratio 0.61, 95% CI: 0.24, 1.12, n=490) but 
this difference was not statistically significant.
Of the 621 patients where hospital mortality sta-
tus was documented, 20 patients died, of which 
10 patients died in intensive care. Ten (50%) of 
these patients were more than 65 years of age, 
19 (95%) had medical comorbidities and 3 (15%) 
were Indigenous Australians. Significant medi-
cal comorbidities in patients who died following 
admission with confirmed influenza were recorded 
as chronic cardiac disease (n=10), chronic respira-
tory disease (n=9), immunosuppression (n=8), 
diabetes (n=4) and renal disease (n=3).
Vaccine coverage and vaccine effectiveness
During this same period, 594 control patients 
were enrolled; vaccination status was ascertained 
in 450 (76%) control patients. In test negative con-
trols during the season, vaccination coverage was 
estimated at 81% (178/221) and 66% (264/401) in 
the elderly and those with medical co-morbidities 
respectively (Table 2).
The effectiveness of the 2013 trivalent seasonal 
influenza vaccine in reducing the risk of hospitali-
sation with influenza was estimated at 50% (95% 
CI: 33%, 63%, P<0.001) in the 2013 influenza sea-
son (Table 4). Vaccine effectiveness was estimated 
to be lower in elderly patients and in those with 
medical co-morbidities (Figure 2).
Discussion
In 2013, we recorded more than 600 admissions 
to the 14 participating hospitals, representing half 
those detected in 2012. Virological surveillance 
of circulating strains suggested that all 3 lineages 
Table 2: Estimated vaccine coverage in influenza cases and test negative controls
Confirmed influenza Test negative acute respiratory illness
n/N % n/N %
All patients 199/514 38.7 283/450 62.9
Age >65 years 100/157 63.7 178/221 80.5
Medical comorbidities 95/143 66.4 172/214 80.4
No medical comorbidities 5/14 35.7 6/7 85.7
Age <65 years 99/357 27.7 105/229 45.9
Medical comorbidities 86/252 34.1 92/187 49.2
No medical comorbidities 13/105 12.4 13/42 31.0
Table 3: Factors associated with admission to 
intensive care in patients hospitalised with 
confirmed influenza
Variable Odds ratio (95% CI) P value
Age >65 years 0.49 (0.29, 0.84) 0.01
Medical comorbidities 1.89 (1.02, 3.50) 0.042
Pregnancy 0.20 (0.04, 0.89) 0.034
Indigenous Australian 2.05 (0.68, 6.19) 0.206
Influenza type
Influenza A 1 (referent) –
Influenza B 1.08 (0.66, 1.77) 0.747
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Table 4: Factors associated with hospitalisation with influenza compared with admission 
associated with non-influenza acute respiratory illnesses
Variable Crude odds ratio P Adjusted odds ratio P
Age ≥ 65 years 0.49 (0.38, 0.62) <0.001 0.62 (0.45, 0.86) 0.003
Medical comorbidities 0.49 (0.36, 0.68) <0.001 0.69 (0.46, 1.04) 0.076
Influenza vaccination 0.39 (0.30, 0.51) <0.001 0.50 (0.37, 0.67) <0.001
Pregnancy 3.02 (1.39, 6.58) 0.005 3.36 (1.09, 10.34) 0.035
Indigenous 1.08 (0.61, 1.90) 0.80 1.08 (0.50, 2.32) 0.84
Figure 2: Estimated vaccine effectiveness 
against hospitalisation for all patients, in 
specified subgroups and against infection with 
influenza subtypes
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(A/H1N1/09, A/H3N2 and B/Yamagata-lineage) 
were detected in varying proportions in different 
states and territories, but vaccine match to circulat-
ing strains was good.9 As the hospitals represented 
in this network represent approximately 12% of the 
national hospital bed capacity, the cases detected 
here are likely to represent approximately 5,400 
admissions nationally. Compared with 2012, the 
2013 season was later (peaking in September in 
2013, compared with July in 2012), younger age 
groups were represented in a higher proportion 
of patients (<65 years: 68% vs 53%), and a higher 
proportion were due to influenza B (30% vs 17%). 
There was a similar number of patients in the 
40–65 year age group but a decrease in all other 
age groups. It should be noted that the relative 
number of cases between jurisdictions does not 
reflect true influenza activity, due to differences in 
the number and size of sentinel hospitals in each 
jurisdiction.
The World Health Organization recommends 
surveillance for severe acute respiratory illness. 
Hospital-based surveillance programs similar 
to FluCAN are operating in many countries.10–15 
By providing information on influenza severity, 
hospital-based surveillance complements commu-
nity– and primary care-based surveillance systems, 
which provide information on the extent of spread.
Influenza vaccine coverage has been estimated 
infrequently in hospitalised patients in Australia.16 
In 2012, we estimated vaccine coverage in 2 separate 
groups of patients: patients with pneumonia prior to 
the influenza season, and patients during the influ-
enza season who had tested negative for influenza. 
The results in these groups were consistent with each 
other, and are similar to the vaccine coverage esti-
mated in 2013. Self-reported vaccination status has 
been shown to slightly overestimate true influenza 
vaccination status.16–18 Community-based estimates 
of influenza vaccine coverage, last reported in 2009, 
have shown similar results that have been consistent 
over time since 2002.19
The test negative study design to estimate vaccine 
effectiveness is becoming increasingly accepted 
and is ideally suited to being incorporated into 
surveillance systems. Two recent papers have 
examined the validity of this design. Foppa et al 
found that the estimates would be robust to most 
assumptions, but bias may be introduced by dif-
ferences in health care-seeking behaviour amongst 
cases and non-cases by vaccine status, strong viral 
interference, or modification of the probability of 
symptomatic illness by vaccine status.20 De Serres 
et al compared estimates from per protocol analy-
ses of 4 randomised controlled trials of live attenu-
ated influenza vaccine, with estimates based on 
the test negative design, and found minimal bias.21 
However, these studies have primarily considered 
vaccine effectiveness in the primary care setting.
Several studies, many of them embedded in 
surveillance systems, are able to provide regular 
estimates of vaccine effectiveness against hospitali-
sation. We previously reported vaccine effective-
ness of 37%–48% in the 2010 and 2011 seasons, 
and of 41% in the 2012 season.7,8 Estimates from 
other hospital-based studies have ranged widely 
from 30% to 71%, in part reflecting smaller sample 
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sizes than in community-based studies.22–25 These 
results reinforce previous findings that vaccination 
coverage in non-elderly patients with comorbidi-
ties is relatively low. Further work is required to 
explore reasons for poor vaccination uptake, 
whether related to poor awareness in patients or 
healthcare providers.
There are several limitations to this study. 
Incomplete case ascertainment is likely due to the 
lack of use of influenza laboratory tests, despite 
the diagnosis of influenza having implications for 
infection control and antiviral use in hospitals. 
Delayed presentations or secondary bacterial 
pneumonia may be associated with false negative 
influenza tests as the influenza infection may be 
cleared at the time of presentation. There may also 
be unmeasured confounding of the association 
between vaccination and admission with influenza, 
a bias that has plagued studies of influenza mor-
tality.26 Although previous studies have suggested 
that self-reported influenza vaccination status only 
slightly overestimates vaccination coverage, we 
have not validated this in our population.16–18
In summary, we detected a smaller number of 
hospital admissions with confirmed influenza in 
a national observational study in 2013 compared 
with 2012. Vaccine coverage was incomplete in at-
risk groups, particularly non-elderly patients with 
medical comorbidities. Our results suggest that the 
2013 seasonal influenza vaccine was moderately 
protective against hospitalisation with influenza.
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